Cameron John Reynolds
President and CEO at VolitionRX Limited
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: VolitionRX Limited, 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
VolitionRX Limited July 17, 202695.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 26, 2026 | VolitionRX Limited | Grant or award | +486,000 | — | — |
| Jan 22, 2026 | VolitionRX Limited | Grant or award | +74,700 | — | — |
| Nov 17, 2025 | VolitionRX Limited | Open-market purchase | +20,000 | $0.35 | $7,000 |
| Oct 14, 2025 | VolitionRX Limited | Open-market purchase | +110,000 | $0.51 | $56,100 |
| Sep 12, 2025 | VolitionRX Limited | Open-market purchase | +15,000 | $0.66 | $9,900 |
| Aug 5, 2025 | VolitionRX Limited | Open-market purchase | +78,125 | $0.64 | $50,000 |
| Jul 24, 2025 | VolitionRX Limited | Grant or award | +200,000 | — | — |
| Jun 12, 2025 | VolitionRX Limited | Open-market purchase | +12,500 | $0.59 | $7,375 |
| May 19, 2025 | VolitionRX Limited | Open-market purchase | +20,000 | $0.44 | $8,800 |
| Mar 26, 2025 | VolitionRX Limited | Open-market purchase | +181,818 | $0.55 | $100,000 |
| Dec 9, 2024 | VolitionRX Limited | Open-market purchase | +139,811 | $0.57 | $79,692 |
| Sep 1, 2024 | VolitionRX Limited | Grant or award | +103,243 | — | — |
| Aug 15, 2024 | VolitionRX Limited | Grant or award | +29,500 | — | — |
| Jun 1, 2024 | VolitionRX Limited | Grant or award | +90,182 | — | — |
| Jan 24, 2024 | VolitionRX Limited | Grant or award | +50,150 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.